Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: Frequency and distribution

Journal of Cutaneous Pathology

Volumn 25, Issue 4, 1998, Pages 204-209

  Hofbauer, Günther F L ^a   Kamarashev, Jivko ^a   Geertsen, Ralf ^a   Böni, Roland ^a   Dummer, Reinhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOPHENOL MONOOXYGENASE; PARAFFIN;

ANTIGEN RETRIEVAL; ARTICLE; CANCER STAGING; CONTROLLED STUDY; CORRELATION FUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; IMMUNOREACTIVITY; MELANOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIBODIES, MONOCLONAL; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FORMALDEHYDE; HUMANS; HUTCHINSON'S MELANOTIC FRECKLE; IMMUNOENZYME TECHNIQUES; MELANOMA; MONOPHENOL MONOOXYGENASE; NEVUS; PARAFFIN EMBEDDING; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN NEOPLASMS; TISSUE FIXATION;

EID: 0031956632     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0560.1998.tb01720.x     Document Type: Article

References (26)

1. Boon T, Vanderbruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996: 183: 725.
2. Maeurer MJ, Storkus WJ, Kirkwood JM, Lotze MT. New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res 1996: 6: 11.
3. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996: 56: 2479.
4. Marchand M, Weynants P, Rankin E, et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995: 63: 883.
5. Bueler H, Mulligan RC. Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE - enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1. Mol Med 1996: 2: 545.
6. Dummer R, Davis-Daneshfar A, Döhring C, Döbbeling U, Burg G. Strategien zur Gentherapie des Melanoms. Hautarzt 1995: 46: 305.
7. Chen YT, Stockert E, Tsang S, Coplan KA, Old LJ. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA 1995: 92: 8125.
8. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KA, Stein H, Mason DY. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984: 32: 219.
9. Hofbauer GFL, Schaefer C, Noppen C, Böni R, Kamarashev J, Spagnioli G, Dummer R. MAGE-3 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. Am J Pathol 1997: 151: 1549.
10. Bystryn JC. The immunobiology of human malignant melanoma. Int J Dermatol 1980: 19: 375.
11. Anichini A, Maccalli C, Mortarini R, et al. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med 1993: 177: 989.
12. Brichard VG, Herman J, Vanpel A, et al. Tyrosinase non-apeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur J Immunol 1996: 26: 224.
13. Brichard V, Van Pel A, Wölfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993: 178: 489.
14. Robbins PF, el-Gamil M, Kawakami Y, Stevens E, Yannelli JR, Rosenberg SA. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 1994: 54: 3124.
15. Wölfel T, Van Pel A, Brichard V, et al. Two tyrosinase non-apeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994: 24: 759.
16. Sato N, Suzuki S, Takimoto H, et al. Monoclonal antibody mat-1 against human tyrosinase can detect melanogenic cells on formalin-fixed paraffin-embedded sections. Pigment Cell Res 1996: 9: 72.
17. Jäger E, Ringhoffer M, Altmannsberger M, et al. Immunoselection in vivo- independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997: 71: 142.
18. Marincola FM, Hijazi YM, Fetsch P, et al. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother 1996: 19: 192.
19. Albino AP. Genes involved in melanoma susceptibility and progression. Curr Opin Oncol 1995: 7: 162.
20. Rosenberg SA. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Annu Rev Med 1996: 47: 481.
21. Gattoni-Celli S, Cole DJ. Melanoma-associated tumor antigens and their clinical relevance to immunotherapy. Semin Oncol 1996: 23: 754.
22. Kawakami Y, Battles JK, Kobayashi T, et al. Production of recombinant MART-1 proteins and specific AntiMART-1 polyclonal and monoclonal antibodies - use in the characterization of the human melanoma antigen MART-1. J Immunol Methods 1997: 202: 13.
23. Sakai C, Kawakami Y, Law LW, Furumura M, Hearing VJ. Melanosomal proteins as melanoma-specific immune targets. Melanoma Res 1997: 7: 83.
24. Gudat F, Zuber M, Dürmüller U, et al. The tumour-associated antigen MAGE-1 is detectable in formalin-fixed paraffin sections of malignant melanoma. Virchows Arch 1996: 429: 77.
25. Chen YT, Stockert E, Jungbluth A, Tsang S, Coplan KA, Scanlan MJ, Old LJ. Serological analysis of Melan-A (MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci USA 1996: 93: 5915.
26. Gown AM, Vogel AM, Hoak D, Gough F, McNutt MA. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 1986: 123: 195.